QQ客服 官方微博 反馈留言

	Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
	Zhang, Fengli; Chen, Huixiao; Du, Jing; Wang, Bin; Yang, Lixiao
刊名	MEDICAL SCIENCE MONITOR
	2018
卷号	24页码:6093-6101
关键词	Antineoplastic Agents Cell Migration Inhibition Metformin
DOI	10.12659/MSM.909745
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4578701
专题	山东大学
作者单位	1.Shandong Univ, Qilu Hosp, Infertil Ctr, Jinan, Shandong, Peoples R China. 2.[Zhang, Fengli 3.Chen, Huixiao 4.Du, Jing 5.Wang, Bin 6.Yang,
推荐引用方式 GB/T 7714	Zhang, Fengli,Chen, Huixiao,Du, Jing,et al. Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway[J]. MEDICAL SCIENCE MONITOR,2018,24:6093-6101.
APA	Zhang, Fengli,Chen, Huixiao,Du, Jing,Wang, Bin,&Yang, Lixiao.(2018).Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.MEDICAL SCIENCE MONITOR,24,6093-6101.
MLA	Zhang, Fengli,et al."Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway".MEDICAL SCIENCE MONITOR 24(2018):6093-6101.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。